Prostatic Hypertrophy, Benign Terminated Phase 3 Trials for Cetrorelix (DB00050)

Also known as: Benign Prostatic Hypertrophy (BPH) / Benign Prostatic Hypertrophy / BPH / Prostatic hypertrophy (benign) / Benign prostatic hyperplasia / Enlarged prostate (benign)

IndicationStatusPhase
DBCOND0029457 (Prostatic Hypertrophy, Benign)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00449150Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)Treatment